Global Rare Disease Drugs Market Overview (2021-2026)

0

DUBLIN, December 16, 2021 / PRNewswire / – The “Global Rare Disease Drugs Market Overview 2021, Analysis and Forecast to 2026, by Manufacturers, Regions, Technology, Application and Product Type” the report was added to ResearchAndMarkets.com offer.

This report describes the global rare disease drugs market size from 2016 to 2020 and its CAGR from 2016 to 2020, and also forecasts its market size to the end of 2026 and its CAGR from 2021 to 2026.

For geography segment, regional supply, demand, major players, the price is presented from 2016 to 2026.

This report covers the following regions:

  • North America
  • South America
  • Asia & Pacific
  • Europe
  • AEM

Key countries for each region are also included such as United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS and Brazil etc.

For competitor segment, the report includes global major players of Rare Disease Medicine as well as some small players.

Information for each competitor includes:

  • Company Profile
  • Main company information
  • SWOT analysis
  • Sales volume, turnover, price and gross margin
  • Market share

Application segment:

  • Hospital pharmacies
  • Specialty pharmacies
  • Retail pharmacies
  • Others

Covered companies:

  • Novartis AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltée.
  • Pfizer Inc.
  • Sanofi SA
  • Alexion Pharma inc.
  • Eli Lilly and company
  • Novo Nordisk A / S
  • AstraZeneca

Main topics covered:

Chapter 1 Executive summary

Chapter 2 Abbreviations and acronyms

Chapter 3 Preface
3.1 Scope of the research
3.2 Research sources
3.2.1 Data sources
3.2.2 Assumptions
3.3 Research method

Chapter 4 Market Landscape
4.1 Market overview
4.2 Classification / Types
4.3 Application / End users

Chapter 5 Market Trend Analysis
5.1 Presentation
5.2 Drivers
5.3 Constraints
5.4 Opportunities
5.5 Threats
5.6 Impact of Covid-19

Chapter 6 Industry Chain Analysis
6.1 Upstream / supplier analysis
6.2 Analysis of drugs against rare diseases
6.2.1 Technology analysis
6.2.2 Cost analysis
6.2.3 Market Channel Analysis
6.3 Downstream buyers / end users

Chapter 7 Latest Market Dynamics
7.1 Latest news
7.2 Merger and acquisition
7.3 Planned / future project
7.4 Policy dynamics

Chapter 8 Trading Analysis
8.1 Export of Rare Disease Medicines by Region
8.2 Import of Rare Disease Medicines by Region
8.3 Trade balance

Chapter 9 Historical and Forecast of Rare Disease Drugs Market in North America (2016-2026)
9.1 Rare Disease Drugs Market Size
9.2 Rare Disease Drug Demand by End Use
9.3 Competition by players / suppliers
9.4 Type and price segmentation
9.5 Analysis of key countries
9.5.1 United States
9.5.2 Canada
9.5.3 Mexico

Chapter 10 Historical and Forecast of Rare Disease Drugs Market in South America (2016-2026)
10.1 Rare Disease Drugs Market Size
10.2 Rare Disease Drug Demand by End Use
10.3 Competition by players / suppliers
10.4 Types and prices segmentation
10.5 Analysis of key countries
10.5.1 Brazil
10.5.2 Argentina
10.5.3 Chile
10.5.4 Peru

Chapter 11 Historical and Forecast of Rare Disease Drugs Market in Asia & Pacific (2016-2026)
11.1 Rare Disease Drugs Market Size
11.2 Rare Disease Drug Demand by End Use
11.3 Competition by players / suppliers
11.4 Types and prices segmentation
11.5 Analysis of key countries
11.5.1 China
11.5.2 India
11.5.3 Japan
11.5.4 South Korea
11.5.5 South East Asia
11.5.6 Australia

Chapter 12 Historical and Forecast of Rare Disease Drugs Market in Europe (2016-2026)
12.1 Rare Disease Drugs Market Size
12.2 Rare Disease Medicines Demand by End Use
12.3 Competition by players / suppliers
12.4 Types and prices segmentation
12.5 Analysis of key countries
12.5.1 Germany
12.5.2 France
12.5.3 UK
12.5.4 Italy
12.5.5 Spain
12.5.6 Belgium
12.5.7 Netherlands
12.5.8 Austria
12.5.9 Poland
12.5.10 Russia

Chapter 13 Historical and Forecast of Rare Disease Drugs in MEA Market (2016-2026)
13.1 Rare Disease Drugs Market Size
13.2 Rare Disease Medicines Demand by End Use
13.3 Competition by players / suppliers
13.4 Types and prices segmentation
13.5 Analysis of key countries
13.5.1 Egypt
13.5.2 Israel
13.5.3 South Africa
13.5.4 Gulf Cooperation Council countries
13.5.5 Turkey

Chapter 14 Global Rare Disease Drugs Market Summary (2016-2021)
14.1 Rare Disease Drugs Market Size
14.2 Rare Disease Drug Demand by End Use
14.3 Competition by players / suppliers
14.4 Types and prices segmentation

Chapter 15 Global Rare Disease Drugs Market Forecast (2021-2026)
15.1 Rare Disease Drugs Market Size Forecast
15.2 Forecasting Demand for Rare Disease Medicines
15.3 Competition by players / suppliers
15.4 Type Segmentation and Price Forecast

Chapter 16 Global Major Vendor Analysis
16.1 Novartis AG
16.1.1 Company Profile
16.1.2 Main Business and Rare Disease Drug Information
16.1.3 SWOT analysis of Novartis AG
16.1.4 Novartis AG Rare Disease Drug Sales, Revenue, Price and Gross Margin (2016-2021)
16.2 Bristol-Myers Squibb Company
16.2.1 Company Profile
16.2.2 Main Business and Rare Disease Drug Information
16.2.3 Bristol-Myers Squibb Company SWOT Analysis
16.2.4 Bristol-Myers Squibb Company Rare Disease Drug Sales, Revenue, Price and Gross Margin (2016-2021)
16.3 Celgene Company
16.3.1 Company Profile
16.3.2 Main Business and Rare Disease Drug Information
16.3.3 SWOT Analysis of Celgene Corporation
16.3.4 Celgene Corporation Rare Disease Drug Sales, Revenue, Price and Gross Margin (2016-2021)
16.4 F. Hoffmann-La Roche Ltée.
16.4.1 Company Profile
16.4.2 Main Business and Rare Disease Drug Information
16.4.3 SWOT analysis by F. Hoffmann-La Roche Ltd.
16.4.4 F. Hoffmann-La Roche Ltd. Rare Disease Drug Sales, Revenue, Price and Gross Margin (2016-2021)
16.5 Pfizer Inc.
16.5.1 Company Profile
16.5.2 Main Business and Rare Disease Drug Information
16.5.3 SWOT Analysis of Pfizer Inc.
16.5.4 Pfizer Inc. Sales, Revenue, Price and Gross Margin of Rare Disease Drugs (2016-2021)
16.6 Sanofi SA
16.6.1 Company Profile
16.6.2 Main Business and Rare Disease Drug Information
16.6.3 SWOT analysis of Sanofi SA
16.6.4 Sanofi SA Rare Disease Medicines Sales, Revenue, Price and Gross Margin (2016-2021)
16.7 Alexion Pharmaceuticals inc.
16.7.1 Company Profile
16.7.2 Main Business and Rare Disease Drug Information
16.7.3 SWOT Analysis of Alexion Pharmaceuticals Inc.
16.7.4 Alexion Pharmaceuticals Inc. Sales, Revenue, Price and Gross Margin of Rare Disease Drugs (2016-2021)
16.8 Eli Lilly and company
16.8.1 Company Profile
16.8.2 Main Business and Rare Disease Drug Information
16.8.3 SWOT Analysis of Eli Lilly and Company
16.8.4 Eli Lilly and Company Rare Disease Drug Sales, Revenue, Price and Gross Margin (2016-2021)
16.9 Novo Nordisk A / S
16.9.1 Company Profile
16.9.2 Main Business and Rare Disease Drug Information
16.9.3 SWOT Analysis of Novo Nordisk A / S
16.9.4 Novo Nordisk A / S Rare Disease Drug Sales, Revenue, Price and Gross Margin (2016-2021)
16.10 AstraZeneca
16.10.1 Company Profile
16.10.2 Main Business and Rare Disease Drug Information
16.10.3 AstraZeneca SWOT Analysis
16.10.4 AstraZeneca Rare Disease Drug Sales, Revenue, Price and Gross Margin (2016-2021)

For more information on this report, visit https://www.researchandmarkets.com/r/ws99cg

Media contact:

Research and markets
Laura Wood, senior
[email protected]

For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1907
Fax (outside the United States): + 353-1-481-1716

SOURCE Research and Markets

Related links

http://www.researchandmarkets.com

Share.

Comments are closed.